Literature DB >> 25879402

'Realworld' use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry.

John W Eikelboom, Jeffrey I Weitz1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25879402     DOI: 10.1160/TH15-02-0158

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  4 in total

1.  Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?

Authors:  S Desmaele; S Steurbaut; P Cornu; R Brouns; A G Dupont
Journal:  Eur J Clin Pharmacol       Date:  2016-06-07       Impact factor: 2.953

Review 2.  New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?

Authors:  María Asunción Esteve-Pastor; Diana Hernández-Romero; Mariano Valdés; Francisco Marín
Journal:  Molecules       Date:  2016-02-27       Impact factor: 4.411

3.  Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).

Authors:  Raffaele De Caterina; Peter Kelly; Pedro Monteiro; Jean Claude Deharo; Carlo de Asmundis; Esteban López-de-Sá; Thomas W Weiss; Johannes Waltenberger; Jan Steffel; Joris R de Groot; Pierre Levy; Ameet Bakhai; Wolfgang Zierhut; Petra Laeis; Michael Kerschnitzki; Paul-Egbert Reimitz; Paulus Kirchhof
Journal:  BMC Cardiovasc Disord       Date:  2019-07-12       Impact factor: 2.298

4.  Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies.

Authors:  Manuel Anguita; Mariano de la Figuera; Alejandro I Pérez Cabeza; Carmen Suarez Fernández
Journal:  Drugs Context       Date:  2019-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.